secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2024-03-13T23:59:59+00:00
Accession:  0001213900-24-022184
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Citius Pharma gets Nasdaq bid-price compliance extension to Sept 9, 2024; annual meeting elects directors
--------------------------------------------------------------------------------

- Nasdaq granted extension until Sept 9, 2024 to regain $1.00 minimum bid price; stock continues trading under CTXR.
- If compliance not achieved by Sept 9, 2024, Nasdaq will issue delisting notice; company can appeal to hearings panel.
- At March 12 annual meeting, all seven director nominees elected (Leonard Mazur, Myron Holubiak, Suren Dutia, Dr. Eugene Holuka, Dennis McGrath, Robert Smith, Carol Webb).
- Stockholders ratified Wolf & Company as auditor for FY ending Sept 30, 2024 with 77.2M votes for, 2.5M against.
- Company evaluating options to regain bid price compliance; no assurance of success.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390024022184/0001213900-24-022184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390024022184/ea0201715-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-022184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer